Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Progyny, Inc. (NASDAQ:PGNY) have been assigned an average recommendation of “Hold” from the thirteen analysts that are currently covering the stock, MarketBeat.com reports. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $24.82.

PGNY has been the topic of several recent analyst reports. Canaccord Genuity Group boosted their target price on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, February 28th. Bank of America boosted their price objective on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Finally, JPMorgan Chase & Co. raised their target price on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th.

Insiders Place Their Bets

In other Progyny news, Chairman David J. Schlanger bought 150,000 shares of the firm’s stock in a transaction dated Thursday, December 26th. The stock was acquired at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the transaction, the chairman now directly owns 228,269 shares in the company, valued at approximately $3,350,988.92. This represents a 191.65 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Progyny

Several hedge funds have recently bought and sold shares of PGNY. Signaturefd LLC lifted its position in Progyny by 1,355.0% in the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock worth $25,000 after buying an additional 1,355 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after acquiring an additional 1,246 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock worth $51,000 after acquiring an additional 1,526 shares in the last quarter. Caitlin John LLC boosted its position in Progyny by 2,974.8% during the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock valued at $57,000 after purchasing an additional 3,183 shares during the last quarter. Finally, Natixis purchased a new position in Progyny in the fourth quarter valued at about $69,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Trading Up 0.9 %

Progyny stock opened at $22.05 on Thursday. Progyny has a 52 week low of $13.39 and a 52 week high of $38.98. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of 38.02, a PEG ratio of 2.39 and a beta of 1.41. The company’s 50-day moving average price is $21.96 and its two-hundred day moving average price is $18.54.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.